Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BTMs and Treatment Efficacy in Postmenopausal Osteoporosis
NCT07242612Completed
- Sponsor
- Khyber Medical University
- Start
- Oct 2025
- Primary completion
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of teriparatide, alendronate, ibandronate and risedronate in osteoporosis (2 arms), sponsored by Khyber Medical University. Primary endpoints: Change in Bone Turnover Markers at 6 months and Change in Bone Mineral Density at 6 months. Started Oct 2025; status: completed.
02
Drugs
teriparatidealendronateibandronaterisedronate
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT07242612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07242612.